We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy (DMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03340675
Recruitment Status : Not yet recruiting
First Posted : November 13, 2017
Last Update Posted : November 14, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

November 3, 2017
November 13, 2017
November 14, 2017
March 2018
April 2019   (Final data collection date for primary outcome measure)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Baseline through 12 months ]
number of subjects with one or more treatment emergent adverse event
Same as current
Complete list of historical versions of study NCT03340675 on ClinicalTrials.gov Archive Site
  • Peak plasma concentration of ifetroban and its acyl glucuronide metabolite after administration [Pharmacokinetics] [ Time Frame: Day 0 (first dose) and at Month 6 (steady state) ]
    Peak plasma concentration of ifetroban and its acyl glucuronide metabolite after administration.
  • Change from baseline in myocardial strain (a sensitive measure of heart function using cardiac MRI) [Efficacy] [ Time Frame: Baseline and 12 months ]
    There should be no change in myocardial strain. Patients with DMD are likely to have an increase in myocardial strain over time (2% or more in 12 months)
  • Change from baseline in forced expiratory volume in 1 second (FEV1) [Pulmonary function] [ Time Frame: Baseline and 12 months ]
    a low FEV1 indicates poor pulmonary function; normal values for FEV1 vary from person to person. Each person has their own predicted FEV1 value.
  • Pediatric Quality of Life (PedQL) Inventory including Neuromuscular module [Quality of life] [ Time Frame: Baseline and 12 months ]
    The 23 items PedQL measure these core dimensions of health as delineated by the World Health Organization, as well as role (school) functioning. Items measured include 1) Physical Functioning (8 items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School Functioning (5 items). Each item is measured on a 5 point Likert scale with 0 indicating never and 4 indicating almost always. The Likert scores are reversed scored and linearly transform to a 0-100 scale with 0=100, 1-75, 2=50, 5=25, and 4=0. A higher score indicates better health-related quality of life.
  • Peak plasma concentration of ifetroban and its acyl glucuronide metabolite after administration [Pharmacokinetics] [ Time Frame: Day 0 (first dose) and at Month 6 (steady state) ]
    Peak plasma concentration of ifetroban and its acyl glucuronide metabolite after administration.
  • Change from baseline in myocardial strain (a sensitive measure of heart function using cardiac MRI) [Efficacy] [ Time Frame: Baseline and 12 months ]
    There should be no change in myocardial strain. Patients with DMD are likely to have an increase in myocardial strain over time (2% or more in 12 months)
  • Change from baseline in forced expiratory volume in 1 second (FEV1) [Pulmonary function] [ Time Frame: Baseline and 12 months ]
    a low FEV1 indicates poor pulmonary function; normal values for FEV1 vary from person to person. Each person has their own predicted FEV1 value.
  • Pediatric Quality of Life Inventory including Neuromuscular module [Quality of life] [ Time Frame: Baseline and 12 months ]
    0-100 scale; the higher the score indicates better health-related quality of life
Not Provided
Not Provided
 
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
An Open-Label, Multicenter, Dose-Ranging Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
This is an open-label, multicenter, dose-ranging study to determine the safety, pharmacokinetics and efficacy of two dose ranges of oral ifetroban in subjects with DMD. DMD patients who meet the inclusion criteria and none of the exclusion criteria will receive oral ifetroban once daily for 12 months.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Dose-ranging study, enrollment onto low dose followed by high dose
Masking: None (Open Label)
Primary Purpose: Treatment
  • Duchenne Muscular Dystrophy
  • Muscular Dystrophies
  • Muscular Dystrophy, Duchenne
  • Muscular Diseases
Drug: Oral Ifetroban
Weight-based dosing
  • Experimental: Oral Ifetroban - Low Dose
    Weight based, once daily oral ifetroban
    Intervention: Drug: Oral Ifetroban
  • Experimental: Oral Ifetroban - High Dose
    Weight based, once daily oral ifetroban
    Intervention: Drug: Oral Ifetroban
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
32
July 2019
April 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males 7 years of age and older with the diagnosis of DMD, defined as phenotype consistent with DMD and either positive genotype, first degree relative with positive genotype, or confirmatory muscle biopsy.
  • Stable dose of oral corticosteroids for at least 12 weeks or has not received corticosteroids for at least 12 weeks.
  • Stable cardiac function defined as change in left ventricular ejection fraction of < 15% and no heart failure admission over the last 12 months; left ventricular ejection fraction 35% or greater by cine cardiac MRI (CMR) or echocardiography; myocardial damage in one or more left ventricular segments evident by late gadolinium enhancement allowed; concurrent angiotensin-converting enzyme inhibitors (ACEI), beta-blocker (BB) or angiotensin receptor blocker (ARB) therapy allowed (selection of which dictated by clinical care) if started three months or greater from first dose of ifetroban without change in dose. Aldosterone receptor antagonists (eg. Spironolactone or eplerenone) allowed if started 12 months or greater from first dose of ifetroban. No changes throughout the study allowed.
  • Use of contraceptives for sexually active males throughout the study
  • Subjects aged 18 years and older, informed consent obtained directly. For subjects ages 7-17 years, both assent from the subject and permission from a parent or guardian.

Exclusion Criteria:

  • Clinically significant illness other than DMD
  • Clinically significant laboratory abnormality not associated with DMD
  • Major surgery within six weeks prior to the first dose of study drug, or planned surgery during this study which would interfere with the ability to perform study procedures
  • Require antiarrhythmic and/or antidiuretic therapy for heart failure
  • A left ventricular ejection fraction (EF) of < 35% by CMR and/or fractional shortening of < 15% based on echocardiography (ECHO) during screening
  • Concurrent use of nitrates, alpha-adrenergic receptor blockers, or phosphodiesterase inhibitors
  • A known bleeding disorder or has received chronic anticoagulant treatment within 2 weeks of study entry
  • Allergy to gadolinium contrast or known renal insufficiency
  • Non-MR compatible implants (e.g. neurostimulator, AICD)
  • Any other condition that could interfere with the subject's participation
Sexes Eligible for Study: Male
7 Years and older   (Child, Adult, Senior)
No
Contact: Ines M Macias-Perez, PhD 6159795778 imaciasperez@cumberlandpharma.com
Contact: Byron Kaelin, RN 6156274121 bkaelin@cumberlandpharma.com
Not Provided
 
 
NCT03340675
CPI-IFE-007
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Cumberland Pharmaceuticals
Cumberland Pharmaceuticals
Vanderbilt University Medical Center
Principal Investigator: Larry Markham, MD Vanderbilt University School of Medicine
Cumberland Pharmaceuticals
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP